William L Herring

Health Solutions

United States

Research Interests

Explore related searches

Professors in United States Professors in Public Health Public Health professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (7)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2022

Year:

2021

Collaborators (9)

Amir Abbas Tahami Monfared

McGill University

CANADA

View details

Vilija Jokubaitis

MONASH UNIVERSITY

AUSTRALIA

View details

Stephanie Barrows

Health Solutions

UNITED STATES

View details

Deirdre Mladsi

Health Solutions

UNITED STATES

View details

Justin Yehuda Garber

Clinical Senior Lecturer

University of Sydney

AUSTRALIA

View details

Mark Slee

Flinders University

AUSTRALIA

View details

Giovanna De Luca

Multiple Sclerosis Centre Medical Coordinator (responsabile Centro SM con incarico di medio alta professionalità)

Ospedale San Raffaele

ITALY

View details

Eduardo Aguera-Morales

Profesor Asociado

Universidad de Córdoba

SPAIN

View details

Justin Carrico

GlaxoSmithKline (United States)

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

William L Herring

Research Interests

Explore related searches

Contact this professor

Articles (7)

Societal Costs and Efficiency of Subcutaneous versus Intravenous Lecanemab in Early Alzheimer’s Disease: A U.S. Cost Comparison Model

Use of patient-reported outcome measures in cost-effectiveness models informing health technology assessments of non-oncology treatments: a review

Cost-Effectiveness of Lovotibeglogene Autotemcel (Lovo-Cel) Gene Therapy for Patients with Sickle Cell Disease and Recurrent Vaso-Occlusive Events in the United States

Going Forward: Potential Impact of Protein-Based COVID-19 Vaccination Coverage on Population Outcomes and Costs in the United States

Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom.

Evaluation of emerging NASH therapies: the impact of treatment efficacy profiles on long-term health outcomes

Estimated Public Health Impact of the Recombinant Zoster Vaccine

Collaborators (9)

Amir Abbas Tahami Monfared

Vilija Jokubaitis

Stephanie Barrows

Deirdre Mladsi

Justin Yehuda Garber

Mark Slee

Giovanna De Luca

Eduardo Aguera-Morales

Justin Carrico

Make your next move.